Blog
RSS FeedPosted by Michael Wonder on 30 Nov 2023
Prevalence and nature of manufacturer-sponsored patient support programs for prescription drugs in Canada: a cross-sectional study
27 November 2023 - Of the 2556 prescription drugs marketed by 89 companies in the study period, 256 (10.0%) had a ...
Posted by Michael Wonder on 20 Nov 2023
Landmark medicines deal to boost nation’s health, save NHS £14 billion, and support research investment
20 November 2023 - Pro-innovation and pro-competition agreement will introduce a new mechanism to support lower industry payment rates for more ...
Posted by Michael Wonder on 07 Nov 2023
Germany, Belgium and France among those hit hardest as Commission’s Pharma-legislation proposals risk Europe losing a third of its share of global R&D by 2040
6 November 2023 - The European Federation of Pharmaceutical Industries and Associations (EFPIA) is publishing new research which assesses the ...
Posted by Michael Wonder on 12 Sep 2023
The Inflation Reduction Act will lead to fewer new medicines
11 September 2023 - The impact of the Inflation Reduction Act on the biopharmaceutical industry is going to be substantial in ...
Posted by Michael Wonder on 25 Aug 2023
Mid year drug price hikes are back despite Inflation Reduction Act
24 August 2023 - It’s almost a tradition. At the start and halfway points of each year, many pharmaceutical companies ...
Posted by Michael Wonder on 14 Aug 2023
How advocates pushed big pharma to cut tuberculosis drug prices
14 August 2023 - The world’s best tuberculosis drug was too expensive for sufferers—until advocates and a YouTube star changed almost ...
Posted by Michael Wonder on 08 Aug 2023
Don’t believe drug companies: 340B is a program worth saving
8 August 2023 - Here we go again: An op-ed column printed in this publication is yet another example of ...
Posted by Michael Wonder on 25 Jul 2023
Peter Mac increases manufacturing centre for gene therapy bringing new hope to cancer patients
25 July 2023 - Australia’s first biomedical manufacturing facility has opened in Melbourne and will boost lifesaving therapy for cancer patients ...
Posted by Michael Wonder on 26 Jun 2023
Biopharma facing two major crises - a huge patent cliff and price controls
26 June 2023 - The recent productivity of the biopharmaceutical industry has been truly remarkable. From 2017 – 2022, 287 new ...
Posted by Michael Wonder on 22 Jun 2023
PhRMA sues Biden administration over Medicare drug price negotiations
21 June 2023 - The pharmaceutical industry’s largest lobbying group on Wednesday filed a lawsuit challenging provisions in the Biden ...
Posted by Michael Wonder on 13 Jun 2023
New report shows how badly big pharma is ripping off American people with publicly funded medications
12 June 2023 - The American people pay the highest prices in the world for lifesaving prescription drugs that they ...
Posted by Michael Wonder on 01 Jun 2023
Pharmaceutical industry ought to justify drug prices on value, not R&D costs
1 June 2023 - Drug companies will often claim they need to charge high prices to recover their research and development ...
Posted by Michael Wonder on 19 Apr 2023
ICER publishes white paper evaluating best practices and potential reforms for white bagging, brown bagging, and site of service policies that seek to address high markup in drug prices
19 April 2023 - White bagging, brown bagging, and site of service policies developed by payers can reduce significant markup costs ...
Posted by Michael Wonder on 13 Apr 2023
‘A global outlier’: how drug firms are fighting back against UK tax increases
13 April 2023 - With the UK tax on net sales of branded medicines quadrupling over the past three years, medicine ...
Posted by Michael Wonder on 13 Apr 2023
Blocking FDA approval of abortion pill could stifle innovation in the biopharma industry, experts say
13 April 2023 - If courts affirm US District Judge Matthew Kacsmaryk’s decision to suspend the FDA’s approval, it could make ...